Abbott Laboratories
81
Plan:
47
70
89
0
10
20
30
40
50
60
70
80
90
100
For the average 401k participant, the 8 point difference between this plan's BrightScope Rating (81) and the top rated plan (89) could equate to:
[How is this calculated?]
[How is this calculated?]
6 additional years of work Up to $26,700 in lost retirement savings.The delay in retirement calculations apply solely to this defined contribution plan and do not take into account other retirement plans and programs offered by this employer.
Retirement Plan Description
Abbott Laboratories Stock Retirement Plan is a defined contribution plan with a profit-sharing component, 401k feature, and ESOP component. This plan has a BrightScope Rating of 81, placing it in the top 15% of all plans in its peer group. This plan is also in the top 15% of plans for Account Balances, Company Generosity, Salary Deferral, and Total Plan Cost. Abbott Laboratories Stock Retirement Plan currently has over 44,800 active participants and over $6.0B in plan assets.
Retirement Plan Details
| Address |
Corporate Benefits, D-589, Ap51
200 Abbott Park Road Abbott Park, IL 60064-6222 |
| Industry | Manufacturing |
| Administrator | Tim Richmond |
| Net Plan Assets | $6,030,000,000 |
| Total Participants | 45,000 |
| Avg Account Balance | $130,000 |
Compare Other Companies in Peer Group
| Novartis Pharmaceuticals | 88.2 |
| Bayer | 87.4 |
| GlaxoSmithKline LLC | 85.8 |
| The Dow Chemical Company | 82.9 |
| Pfizer | 81.8 |
| Eli Lilly and Company | 79.2 |
Top 3 Funds in this 401k
| 1. | Abbott Laboratories Common Stock | 36% |
| 2. | Total Short-Term Investments | 10% |
| 3. | American Funds Growth Fund of America | 8% |
Plan Service Providers
| Insurance Carrier | Prudential |
| Insurance Carrier | Aegon |
| Insurance Carrier | MetLife |
| Insurance Carrier | Jackson National Life |
| Insurance Carrier | Pacific Life Insurance |
| Insurance Carrier | Hartford |
| Insurance Carrier | Principal Financial Group |
| Corporate Trustee | Mercer |
| Recordkeeper | Mercer |
| Auditor | Grant Thornton LLP |
Comments